NCT06953791RecruitingPhase 2
Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Patients
Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Standard of Care or an Adapted Crohn's Disease Exclusion Diet With Partial Enteral Nutrition in Adult Patients
Source: ClinicalTrials.gov · Last updated 5 Feb 2026
Brief summary (registry, in English)
Crohn's disease (CD), a type of inflammatory bowel disease (IBD), is on the rise globally. Although medical treatments have advanced, CD still leads to significant health issues due to disease progression and medication side effects. Exclusive enteral nutrition (EEN) is a recommended first-line treatment for pediatric CD, proving more effective than oral corticosteroids without side effects. However, EEN demands strict adherence, making it challenging for patients, particularly adults. In 2019, Levine et al. found that a combination of a specific diet (CD exclusion diet, CDED) and partial enteral nutrition (PEN) was as effective as EEN in inducing remission in pediatric patients, with better tolerance and adherence. CDED focuses on whole foods and aims to minimize harmful dietary components affecting the gut. In clinical practice, an adapted CDED (aCDED) has been used to provide more food choices, but it lacks validation in clinical trials. An aCDED that considers regional and seasonal food variations could enhance patient adherence and align with modern dietary preferences. This study aims to compare the quality of life during a flare up of Crohn's disease treated with standard of care or an adapted Crohn's disease exclusion diet with partial enteral nutrition in adult patients.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (estimated)
- First submitted
- 4 Jan 2024
- Start date
- 1 Feb 2026
- Primary completion date
- 1 Feb 2028
- Lead sponsor
- University Hospital Tuebingen
- Diseases
- Crohn's disease
- NCT number
- NCT06953791
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 52
- From 1 Feb 2026 to the primary completion date, 1 Feb 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have received corticosteroids of any kind in the previous 4 weeks
- Patients who have started an immunomodulator in the previous 8 weeks
- Patients who have undergone an intestinal resection
Other illness
- Patients with with minimal disease activity (CDAI \<150) or severe disease (CDAI \>450)
- Isolated large bowel disease iinvolving the recto-sigmoid or descending colon
- Patients with penetrating disease (abscess or fistula)
- Active perianal disease
- Active extraintestinal disease (e.g. joint disease)
- History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product.
Other
- Any current biological or small molecule treatment
- Fixed stricture or small bowel obstruction
- Normal fecal calprotectin
- Sclerosing cholangitis
- Women during pregnancy and lactation Participation in other clinical trials or observation period of competing trials.
Who the study is looking for
- Must be ≥ 18 years at the time of signing the informed consent.
- Macroscopic small bowel involvement, or isolated large bowel disease confined to the right or transverse colon confirmed by endoscopy
- Patients with a Crohn's disease activity index (CDAI) of ≥ 150
- Patients will not be excluded if they have received 5ASA or an immunomodulator for \> 8 weeks and the dose is stable, or if they start a thiopurine concurrently, as thiopurines are not considered sufficient to induce remission in active disease before 8 weeks as an isolated therapy
- Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures
- Able to adhere to the study visit schedule and other protocol requirements
- All subjects must agree to refrain from donating blood while on study drugs
- All subjects must agree not to share medication.
- Subject (male or female) is willing to use highly effective contraceptive methods during treatment and for 28 days (male or female) after the end of treatment
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitätsklinik Tübingen Coordinator of this site? Confirm its status | Tübingen | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.